



**Australian Government**  
**Department of Health and Aged Care**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	199134	Ginsana
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	SFI Australasia	
<b>Postal Address</b>	PO Box 1027, CROWS NEST, NSW, 1585 Australia	
<b>ARTG Start Date</b>	6/07/2012	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . Ginsana

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	10/06/2020
---------------------	-------------------------	-----------------------	------------

### Permitted Indications

Maintain/support energy levels  
Maintain/support energy production  
Maintain/support physical endurance/capacity/stamina  
Maintain/support vitality  
Relieve weariness/tiredness/fatigue/feeling of weakness  
Relieve weariness/tiredness/fatigue/feeling of weakness  
Maintain/support general health and wellbeing  
Maintain/support immune system health  
Enhance/improve/promote immune defence/immunity  
Helps enhance/improve/promote immune system function  
Maintain/support healthy immune system function  
Helps stimulate a healthy immune system response  
Aids/assists the body to cope with environmental stress  
Support healthy body stress recovery  
Maintain/support cognitive function/mental function

### Indication Requirements

Product presentation must not imply or refer to chronic fatigue syndrome.

Label statement: If symptoms persist, talk to your health professional.

Product presentation must not imply or refer to serious immunological diseases.

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

If product is indicated for weight loss, label statement: When used in conjunction with a program of reduced intake of dietary calories and increased physical activity.

Public Summary



**Australian Government**  
**Department of Health and Aged Care**  
 Therapeutic Goods Administration

**Standard Indications**

No Standard Indications included on Record

**Specific Indications**

No Specific Indications included on Record

**Warnings**

(If medicine contains one sugar) contains [insert name of sugar] OR (If medicine contains two or more sugars) Contains sugars [or words to that effect].  
 If symptoms persist consult your healthcare practitioner (or words to that effect).  
 Contains lactose (or words to that effect).

**Additional Product information**

**Container information**

Type	Material	Life Time	Temperature	Closure	Conditions
Blister Pack	Not recorded	Not recorded	Not recorded	Neither child resistant closure nor restricted flow insert	Not recorded

**Pack Size/Poison information**

Pack Size	Poison Schedule

**Components**

**1 . Formulation 1**

<b>Dosage Form</b>	Capsule, hard
<b>Route of Administration</b>	Oral

**Visual Identification**

**Active Ingredients**

<b>Panax ginseng root Extract dry concentrate</b>	<b>100 mg</b>
Equivalent: Panax ginseng (Dry)	212.5 mg

**Other Ingredients (Excipients)**

- chlorophyllin-copper complex
- Gelatin
- magnesium stearate
- mannitol
- silicon dioxide
- titanium dioxide

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary